Next Article in Journal
Analysis of Transcriptional Regulation of the Human miR-17-92 Cluster; Evidence for Involvement of Pim-1
Next Article in Special Issue
Enhanced Inhibition of Bladder Cancer Cell Growth by Simultaneous Knockdown of Antiapoptotic Bcl-xL and Survivin in Combination with Chemotherapy
Previous Article in Journal
UV Radiation and the Skin
Previous Article in Special Issue
Autophagy in Prostate Cancer and Androgen Suppression Therapy
Int. J. Mol. Sci. 2013, 14(6), 12249-12272; doi:10.3390/ijms140612249
Review

Thrombospondin-1 in Urological Cancer: Pathological Role, Clinical Significance, and Therapeutic Prospects

*  and
Received: 25 April 2013; in revised form: 3 June 2013 / Accepted: 3 June 2013 / Published: 7 June 2013
(This article belongs to the Special Issue Molecular Research in Urology)
View Full-Text   |   Download PDF [370 KB, uploaded 19 June 2014]   |   Browse Figures
Abstract: Angiogenesis is an important process for tumor growth and progression of various solid tumors including urological cancers. Thrombospondins (TSPs), especially TSP-1, are representative “anti”-angiogenic molecules and many studies have clarified their pathological role and clinical significance in vivo and in vitro. In fact, TSP-1 expression is associated with clinicopathological features and prognosis in many types of cancers. However, TSP-1 is a multi-functional protein and its biological activities vary according to the specific tumor environments. Consequently, there is no general agreement on its cancer-related function in urological cancers, and detailed information regarding regulative mechanisms is essential for a better understanding of its therapeutic effects and prognostic values. Various “suppressor genes” and “oncogenes” are known to be regulators and TSP-1-related factors under physiological and pathological conditions. In addition, various types of fragments derived from TSP-1 exist in a given tissue microenvironment and TSP-1 derived-peptides have specific activities. However, a detailed pathological function in human cancer tissues is not still understood. This review will focus on the pathological roles and clinical significance of TSP-1 in urological cancers, including prostate cancer, renal cell carcinoma, and urothelial cancer. In addition, special attention is paid to TSP-1-derived peptide and TSP-1-based therapy for malignancies.
Keywords: thrombospondin; urological cancer; TSP-1-derived peptide; therapy thrombospondin; urological cancer; TSP-1-derived peptide; therapy
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Miyata, Y.; Sakai, H. Thrombospondin-1 in Urological Cancer: Pathological Role, Clinical Significance, and Therapeutic Prospects. Int. J. Mol. Sci. 2013, 14, 12249-12272.

AMA Style

Miyata Y, Sakai H. Thrombospondin-1 in Urological Cancer: Pathological Role, Clinical Significance, and Therapeutic Prospects. International Journal of Molecular Sciences. 2013; 14(6):12249-12272.

Chicago/Turabian Style

Miyata, Yasuyoshi; Sakai, Hideki. 2013. "Thrombospondin-1 in Urological Cancer: Pathological Role, Clinical Significance, and Therapeutic Prospects." Int. J. Mol. Sci. 14, no. 6: 12249-12272.


Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert